Publications by authors named "D R Horowitz"

Purpose: To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer.

Methods: A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided the evidence base for this guideline. An ASCO Expert Panel reviewed this evidence and came to consensus on a set of evidence-based recommendations.

View Article and Find Full Text PDF

Purpose: Radiation oncologists are known to be burdened with prior authorization and insurance denials more than other medical specialties. This analysis sought to use publicly available data and determine whether Medicare Advantage plans are inappropriately denying radiation therapy (RT) services more than other health services.

Methods And Materials: Data from the Appeals Decision Search on the Centers for Medicare & Medicaid Services website were extracted from 2022 through June 2024.

View Article and Find Full Text PDF

Purpose/objectives: Retrospective analysis suggests that dose escalation to a biologically effective dose of more than 70 Gy may improve overall survival in patients with pancreatic ductal adenocarcinoma (PDAC), but such treatments in practice are limited by proximity of organs at risk (OARs). We hypothesized that CT-guided online adaptive radiotherapy (OART) can account for interfraction movement of OARs and allow for safe delivery of ablative doses.

Materials/methods: This is a single institution retrospective analysis of patients with PDAC treated with OART on the Ethos platform (Varian Medical Systems, a Siemens Healthineers Company, Palo Alto).

View Article and Find Full Text PDF
Article Synopsis
  • * A meta-analysis of 6 randomized trials involving 1,204 patients found that alkylating chemotherapy improves progression-free survival (PFS) for IDH-wt tumors when combined with radiotherapy, but shows no significant overall survival (OS) benefit.
  • * In contrast, IDH-mutant gliomas benefit significantly from alkylating chemotherapy, with substantial improvements in both PFS and OS, indicating a key difference in treatment effectiveness between the two glioma types
View Article and Find Full Text PDF